UK markets close in 1 hour 16 minutes

Northwest Biotherapeutics, Inc. (NBYB.SG)

Stuttgart - Stuttgart Delayed price. Currency in EUR
Add to watchlist
0.3940-0.0120 (-2.96%)
As of 02:36PM CEST. Market open.

Northwest Biotherapeutics, Inc.

4800 Montgomery Lane
Suite 800
Bethesda, MD 20814
United States
240 497 9024
https://www.nwbio.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 25

Key executives

NameTitlePayExercisedYear born
Ms. Linda F. Powers J.D.Chairperson, CEO, President, CFO & Chief Accounting Officer859.87kN/A1956
Dr. Alton L. Boynton Ph.D.Founder, Chief Scientific Officer, Secretary & Director348.59kN/A1945
Dr. Marnix L. Bosch M.B.A., Ph.D.Chief Technical Officer421.66k68.79k1959
Mr. Leslie J. GoldmanSenior VP & General Counsel673.95kN/A1945
Mr. David InnesVice President of Investor RelationsN/AN/AN/A
Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

Northwest Biotherapeutics, Inc., a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer. Its lead product, DCVax-L, which has completed Phase III clinical trials to treat Glioblastoma multiforme brain cancer. The company also develops DCVax-Direct, which is in Phase I/II clinical trials to treat inoperable solid tumors. The company was founded in 1996 and is headquartered in Bethesda, Maryland.

Corporate governance

Northwest Biotherapeutics, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.